<div id="readability-page-1"><p>Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $24.26 and last traded at $23.9230, with a volume of 86224 shares changing hands. The stock had previously closed at $22.99.</p><div><p><span></span><span>Get <strong>Tyra Biosciences</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><p>Several equities analysts have issued reports on the stock. HC Wainwright  restated a &#34;buy&#34; rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, August 22nd. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded Tyra Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 6th. Oppenheimer  reaffirmed an &#34;outperform&#34; rating and set a $36.00 target price on shares of Tyra Biosciences in a research report on Wednesday, September 10th. Finally, Raymond James Financial started coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They issued a &#34;strong-buy&#34; rating and a $35.00 price target on the stock. One research analyst  has rated the stock with a Strong Buy rating, five have given a Buy rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $33.17.</p><p><b>Get Our Latest Research Report on TYRA</b></p><h2>Tyra Biosciences Stock Performance</h2><p>The business has a 50 day moving average price of $17.93 and a 200-day moving average price of $13.55. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -13.25 and a beta of 1.09. </p><p>Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50).  As a group, equities analysts predict that  Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year. </p><h2>Insider Transactions at Tyra Biosciences</h2><p>In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of the firm's stock in a transaction on Friday, November 21st. The shares were sold at an average price of $20.25, for a total value of $4,999,137.75. Following the completion of the sale, the director directly owned 3,833,425 shares in the company, valued at approximately $77,626,856.25. This trade represents a 6.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.20% of the stock is currently owned by corporate insiders. </p><h2>Hedge Funds Weigh In On Tyra Biosciences</h2><p>A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Commodore Capital LP lifted its holdings in shares of  Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company's stock worth $29,667,000 after purchasing an additional 2,150,000 shares in the last quarter.  Vestal Point Capital LP increased its stake in  Tyra Biosciences by 190.9% during the 1st quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company's stock valued at $26,782,000 after purchasing an additional 1,889,829 shares in the last quarter.  Caligan Partners LP raised its holdings in  Tyra Biosciences by 266.8% during the third quarter. Caligan Partners LP now owns 696,825 shares of the company's stock worth $9,749,000 after buying an additional 506,875 shares during the last quarter.  Sio Capital Management LLC lifted its stake in shares of  Tyra Biosciences by 94.5% in the second quarter. Sio Capital Management LLC now owns 810,274 shares of the company's stock valued at $7,754,000 after buying an additional 393,657 shares in the last quarter.  Finally, Balyasny Asset Management L.P. increased its position in shares of  Tyra Biosciences by 139.8% during the second quarter. Balyasny Asset Management L.P. now owns 583,386 shares of the company's stock worth $5,583,000 after acquiring an additional 340,142 shares in the last quarter. Institutional investors own  84.14% of the company's stock. </p><h2>About Tyra Biosciences</h2> (Get Free Report)<p>Tyra Biosciences <span>NASDAQ: TYRA<span></span></span> is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.  </p><p>The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Tyra Biosciences</li><li>The 3 Best Blue-Chip Stocks to Buy Now</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li><li>How Technical Indicators Can Help You Find Oversold Stocks </li><li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li><li>3 Warren Buffett Stocks to Buy Now</li><li>TL;DR: Why Reddit is the New Growth Stock to Beat</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tyra Biosciences Right Now?</h2><p>Before you consider Tyra Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.</p><p>While Tyra Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TYRA

<p>Tyra Biosciences (NASDAQ:TYRA) hit a new 52-week high, trading as high as $24.26. Analysts have mixed ratings: HC Wainwright and Oppenheimer give 'buy' ratings with targets of $30 and $36, respectively, while Weiss Ratings gives a 'sell' rating. The company has a market cap of $1.32 billion and reported a Q3 EPS of ($0.50). Insider Robert J. More sold 246,871 shares. Institutional investors own 84.14% of the stock. Tyra focuses on precision oncology therapies for genetically defined cancers.</p>

Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week High - Here's What Happened